At FutuRx, Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Israeli Innovation Authority of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines by applying a unique structure of equally balanced partnership among its three founding organizations.

FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure. FutuRx management, together with its founders, will establish and fully support the companies via its in-house laboratory and management facility.